Published in PLoS Comput Biol on August 09, 2012
A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions. Drug Saf (2015) 1.54
Mining clinical text for signals of adverse drug-drug interactions. J Am Med Inform Assoc (2013) 1.38
Development and evaluation of an ensemble resource linking medications to their indications. J Am Med Inform Assoc (2013) 1.28
Informatics confronts drug-drug interactions. Trends Pharmacol Sci (2013) 1.28
Medication-wide association studies. CPT Pharmacometrics Syst Pharmacol (2013) 1.27
Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness. J Biomed Semantics (2013) 1.22
Text mining for adverse drug events: the promise, challenges, and state of the art. Drug Saf (2014) 1.22
Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf (2014) 1.13
Systematic prediction of pharmacodynamic drug-drug interactions through protein-protein-interaction network. PLoS Comput Biol (2013) 1.13
Functional evaluation of out-of-the-box text-mining tools for data-mining tasks. J Am Med Inform Assoc (2014) 1.10
Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. J Am Med Inform Assoc (2014) 1.01
Using semantic predications to uncover drug-drug interactions in clinical data. J Biomed Inform (2014) 0.97
DDI-CPI, a server that predicts drug-drug interactions through implementing the chemical-protein interactome. Nucleic Acids Res (2014) 0.89
Learning signals of adverse drug-drug interactions from the unstructured text of electronic health records. AMIA Jt Summits Transl Sci Proc (2013) 0.89
A method for systematic discovery of adverse drug events from clinical notes. J Am Med Inform Assoc (2015) 0.88
Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach. Clin Pharmacol Ther (2015) 0.87
The potential of translational bioinformatics approaches for pharmacology research. Br J Clin Pharmacol (2015) 0.86
Label Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects. Sci Rep (2015) 0.85
Systematic prediction of drug combinations based on clinical side-effects. Sci Rep (2014) 0.84
Natural Language Processing for EHR-Based Pharmacovigilance: A Structured Review. Drug Saf (2017) 0.83
Co-prescription trends in a large cohort of subjects predict substantial drug-drug interactions. PLoS One (2015) 0.81
Drug combination therapy increases successful drug repositioning. Drug Discov Today (2016) 0.80
Extraction of pharmacokinetic evidence of drug-drug interactions from the literature. PLoS One (2015) 0.79
Feasibility of Prioritizing Drug-Drug-Event Associations Found in Electronic Health Records. Drug Saf (2016) 0.79
A Mixture Dose-Response Model for Identifying High-Dimensional Drug Interaction Effects on Myopathy Using Electronic Medical Record Databases. CPT Pharmacometrics Syst Pharmacol (2015) 0.79
A novel algorithm for analyzing drug-drug interactions from MEDLINE literature. Sci Rep (2015) 0.79
Graphic Mining of High-Order Drug Interactions and Their Directional Effects on Myopathy Using Electronic Medical Records. CPT Pharmacometrics Syst Pharmacol (2015) 0.78
From Molecules to Patients: The Clinical Applications of Translational Bioinformatics. Yearb Med Inform (2015) 0.76
Phenotyping Adverse Drug Reactions: Statin-Related Myotoxicity. AMIA Jt Summits Transl Sci Proc (2015) 0.75
Characterization of the mechanism of drug-drug interactions from PubMed using MeSH terms. PLoS One (2017) 0.75
Database: A New Article Type in CPT: Pharmacometrics & Systems Pharmacology. CPT Pharmacometrics Syst Pharmacol (2015) 0.75
Predicting potential drug-drug interactions by integrating chemical, biological, phenotypic and network data. BMC Bioinformatics (2017) 0.75
Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions. Mol Pharm (2016) 0.75
Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA (1995) 20.12
DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res (2010) 13.68
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Analysing biological pathways in genome-wide association studies. Nat Rev Genet (2010) 6.63
Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med (2010) 4.32
Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA (2003) 4.00
Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov (2005) 2.81
A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc (2011) 2.53
Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf (2010) 2.46
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol (2008) 2.23
Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf (2007) 2.20
Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics (2010) 1.87
Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf (1993) 1.75
Using a shallow linguistic kernel for drug-drug interaction extraction. J Biomed Inform (2011) 1.59
Discovery and explanation of drug-drug interactions via text mining. Pac Symp Biocomput (2012) 1.53
Incidence, predictors and associated outcomes of rhabdomyolysis after kidney transplantation. Nephrol Dial Transplant (2009) 1.52
A linguistic rule-based approach to extract drug-drug interactions from pharmacological documents. BMC Bioinformatics (2011) 1.37
Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther (2008) 1.30
Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf (2007) 1.27
Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy (1998) 1.25
Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy (2010) 1.21
Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther (2010) 1.16
Computing with evidence Part II: An evidential approach to predicting metabolic drug-drug interactions. J Biomed Inform (2009) 1.13
Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther (2011) 1.11
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos (2009) 1.11
Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood (2003) 20.10
Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. Nature (2005) 12.56
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Whole-genome mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic compartments in human embryonic stem cells. Cell Stem Cell (2007) 7.05
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Structure of a glutamate transporter homologue from Pyrococcus horikoshii. Nature (2004) 6.02
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet (2002) 3.95
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2005) 3.63
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology (2004) 3.27
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 3.08
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet (2010) 2.95
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res (2006) 2.63
3,5-Dihydr-oxy-N'-[(2-hydr-oxy-1-naph-thyl)methyl-ene]benzohydrazide. Acta Crystallogr Sect E Struct Rep Online (2007) 2.57
Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Womens Health (Larchmt) (2009) 2.54
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
High-definition chromocolonoscopy vs. high-definition white light colonoscopy for average-risk colorectal cancer screening. Am J Gastroenterol (2010) 2.47
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol (2007) 2.45
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
Structure and mechanism of an amino acid antiporter. Science (2009) 2.40
Workplace and individual risk factors for carpal tunnel syndrome. Occup Environ Med (2011) 2.39
Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol (2008) 2.36
High colonoscopic prevalence of proximal colon serrated polyps in average-risk men and women. Gastrointest Endosc (2011) 2.22
Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer (2004) 2.22
Crystal structure and association behaviour of the GluR2 amino-terminal domain. EMBO J (2009) 2.19
Whole genome DNA methylation analysis based on high throughput sequencing technology. Methods (2010) 2.17
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Protection of the flavonoid fraction from Rosa laevigata Michx fruit against carbon tetrachloride-induced acute liver injury in mice. Food Chem Toxicol (2012) 2.11
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med (2008) 2.05
Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation. Clin Cancer Res (2005) 2.02
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat (2007) 1.92
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol (2012) 1.91
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol (2008) 1.91
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet (2011) 1.91
Cytokines link Toll-like receptor 4 signaling to cardiac dysfunction after global myocardial ischemia. Ann Thorac Surg (2008) 1.91
Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther (2004) 1.89
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics (2007) 1.84
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
Numerical investigations of transient heat transfer characteristics and vitrification tendencies in ultra-fast cell cooling processes. Cryobiology (2006) 1.80
Axon regeneration pathways identified by systematic genetic screening in C. elegans. Neuron (2011) 1.78
Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol (2007) 1.76
Adequacy of hospital discharge summaries in documenting tests with pending results and outpatient follow-up providers. J Gen Intern Med (2009) 1.75
RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22,399 subjects. Breast Cancer Res Treat (2010) 1.74
Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev (2012) 1.73
Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis. Breast Cancer Res Treat (2010) 1.70
Uptake, translocation, and accumulation of manufactured iron oxide nanoparticles by pumpkin plants. J Environ Monit (2008) 1.67
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology (2003) 1.65
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
Cohort mortality study of workers at seven beryllium processing plants: update and associations with cumulative and maximum exposure. Occup Environ Med (2010) 1.62
A new method for estimating the retention of selected smoke constituents in the respiratory tract of smokers during cigarette smoking. Inhal Toxicol (2007) 1.61
Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res (2006) 1.61
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry (2008) 1.59
Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada. J Am Coll Cardiol (2003) 1.56
A comparison of infant hair, cord blood and meconium analysis to detect fetal exposure to environmental pesticides. Environ Res (2007) 1.55
Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clin Chem (2013) 1.54
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Airflows around oxygen masks: A potential source of infection? Chest (2006) 1.53
Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res (2004) 1.53
DJ-1 may contribute to metastasis of non-small cell lung cancer. Mol Biol Rep (2011) 1.52
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos (2002) 1.52
Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther (2004) 1.51
Maternal hair--an appropriate matrix for detecting maternal exposure to pesticides during pregnancy. Environ Res (2006) 1.49
A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology. BMC Genomics (2008) 1.49
Independent influence of dietary protein on markers of kidney function and disease in obesity. Kidney Int (2010) 1.48
Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood (2005) 1.47
Hospitalization for community-acquired pneumonia in Alberta First Nations Aboriginals compared with non-First Nations Albertans. Can Respir J (2004) 1.46
Glycemic variability in gestational diabetes mellitus and its association with β cell function. Endocrine (2012) 1.46
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother (2009) 1.46
Lack of an association between AURKA T91A polymorphisms and breast cancer: a meta-analysis involving 32,141 subjects. Breast Cancer Res Treat (2010) 1.46
Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer (2004) 1.45
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 1.44
Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. J Hepatol (2008) 1.43
Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. Chest (2009) 1.41
Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat (2007) 1.41
Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials. Aging Male (2013) 1.40
Reduced methadone clearance during aromatase inhibition. J Clin Psychopharmacol (2012) 1.39
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics (2003) 1.39